NYSE · HAE
Haemonetics Corporation
$119.79+$1.47 (+1.24%)
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
Loading market information…
NYSE · WRBY · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Warby Parker Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Warby Parker Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Warby Parker Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Warby Parker Inc. operates as a purveyor of optical products and related services. Their extensive product line includes prescription eyeglasses, sunglasses, and contact lenses, alongside specialized lens options such as light-responsive (photochromic) and blue-light-filtering variants. Customers can also acquire a variety of accessories, including protective cases, lens care kits equipped with anti-fog spray, pouches, and individual anti-fog lens sprays. Beyond product sales, Warby Parker facilitates direct-to-consumer eye examinations and vision assessments. These services are accessible through their physical retail locations, online platform, and dedicated mobile applications. By May 16, 2022, the company had established a network of 160 brick-and-mortar stores across the United States and Canada. Originally incorporated as JAND, Inc. in 2009, the organization officially rebranded to Warby Parker Inc. in June 2021. Its corporate headquarters are situated in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | $0.120.0% vs estimate | $223.78M-0.69% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.01-66.67% vs estimate | $190.64M+1.61% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.050.0% vs estimate | $192.45M+1.21% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $29.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$119.79+$1.47 (+1.24%)
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
$41.25+$0.66 (+1.63%)
Concentra Group Holdings Parent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
$126.52-$0.03 (-0.02%)
Integer Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.24% below the high.
$168.65+$2.26 (+1.36%)
ICU Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.55% below the high.
$8.91+$1.99 (+28.76%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.44% below the high.
$28.84+$0.06 (+0.21%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.62% below the high.
$85.27+$2.40 (+2.9%)
LeMaitre Vascular, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.74% below the high.
$9.61+$0.17 (+1.8%)
DENTSPLY SIRONA Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.89% below the high.
